MCO-010 demonstrated positive topline results in vision improvement in patients with permanent and severe vision loss from advanced retinitis pigmentosa, according to a press release from Nanoscope Therapeutics.
The mutation-agnostic gene therapy also demonstrated sustained durability after a single intravitreal injection, with improvements in visual function persisting or increasing after week 52 of the 2-year phase 2b RESTORE trial.
“MCO-010 would, for the first time, provide ophthalmologists a treatment option that actually gives vision back to the patients suffering permanent vision